One of the recent advances in diabetes treatment is the discovery of the incretin-insulin pathway, which involves two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This evidence concerns the gene INS and diabetes mellitus.